Hints and tips:
...Abbott announced on Wednesday that it would break into a pharmaceutical company (with $18bn in sales) and a medical products company selling nutritionals, generic drugs, diagnostics, vascular devices and...
...Thailand’s military-installed government intends to break the patent of a second-line HIV/Aids drug and a cardio-vascular drug, alarming major Western pharmaceutical companies concerned about Bangkok’s growing...
...Medical products sales increased nearly 18 percent in the second quarter, led by double-digit growth in Abbott’s Vascular, International Nutritionals, Molecular and Point of Care businesses....
...Abbott’s issue this week was its biggest ever - and the fourth largest in the US market this year - and will help fund its acquisition of Guidant’s vascular business....
...In the US, Abbott Laboratories, the drugs group, plans to sell $4bn of bonds in a three-part issue to help refinance debt used in its takeover of Guidance’s vascular business, according to bankers....
...By lining up Abbott Laboratories as the buyer for Guidant’s vascular intervention and endovascular businesses, Boston should be able to speed up antitrust approvals....
...Boston said Abbott agreed to pay $4.1bn for Guidant’s vascular intervention and endovascular businesses, up from $3.8bn....
...The deal with Abbott involves the sale of Guidant’s vascular intervention and endovascular businesses for $4.3bn in cash....
International Edition